Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05837221 · ClinicalTrials.gov registry record
Microbiome in Head and Neck Squamous Cell Carcinoma
A clinical trial of Head and Neck Cancer and Oral Cancer, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT05837221: Recruiting study of Head and Neck Cancer and Oral Cancer, sponsored by University of Colorado, Denver.
NCT05837221 is a study of Head and Neck Cancer and Oral Cancer that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 60 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05837221, a study of Head and Neck Cancer and Oral Cancer, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.
Primary Outcome
Stool and saliva samples will be collected from participants, allowing us to reproduce human dysbiosis and analyze whether HNSCC affects one's microbiome composition. Metagenomic sequencing will be conducted through use of DNA extraction, library generation and Illumina sequencing. At least 30 million paired-end 2x150bp metagenomic reads will be generated per sample using the Illumina NovaSeq platform.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Metagenomic sequencing
- DIAGNOSTIC_TEST Metabolic analysis
Study Locations (1)
Colorado
- University of Colorado Cancer Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-05-23 |
| Est. Completion | 2028-10 |
What NCT05837221 shows while recruiting
NCT05837221 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (77% lower).
The record links to 4 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Metagenomic sequencing is the first listed.
NCT05837221 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT05837221 about?
NCT05837221 is a clinical study titled "Microbiome in Head and Neck Squamous Cell Carcinoma". This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.
What is the current status of trial NCT05837221?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2025-05-23. Estimated completion is 2028-10.
What conditions does trial NCT05837221 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Oral Cancer, Lip Cancer, Pharynx Cancer.
What interventions are being tested in trial NCT05837221?
The interventions under investigation include: Metagenomic sequencing (DIAGNOSTIC_TEST), Metabolic analysis (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05837221?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05837221 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05837221's enrollment target sits among peer trials
60 115th of 250 higher than 131 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
3D Specimen Maps for RT Planning
RECRUITING
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck
RECRUITING · NA
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI